The Corporate Reputation of Pharma Companies, 2016: from the Perspective of 99 Spanish Patient Groups (3rd Edition)

  • ID: 4416861
  • Report
  • 94 pages
  • PatientView
1 of 4

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Eli Lilly
  • GSK
  • Janssen
  • Merck & Co
  • MORE

These results are derived from a global review of pharma’s corporate reputation (conducted November 2016 to early-February 2017).
The report is based on the opinions of 99 Spanish patient groups.
The specialty areas of the Spanish patient groups were: mental health (11); dementia (9); HIV/AIDS (8); rare diseases (8); diabetes (6); and others.

11 pharma companies are included in this 2016 Spain analysis:

  •  AbbVie
  •  Bayer
  •  Eli Lilly
  •  GSK
  •  Janssen
  •  Merck & Co
  •  Novartis
  •  Pfizer
  •  Roche
  •  Sandoz
  •  Sanofi

The 11 companies were chosen because a minimum of 19 Spanish patient groups declared familiarity with each one.
Comments on pharma's corporate reputation were provided by 47 Spanish patient groups, with expertise in the following specialty areas: arthritis; cancer; cystic fibrosis; dementia; diabetes; disability; fibromyalgia; gastrointestinal conditions; haemophilia; heart/circulatory conditions; HIV/AIDS; other immune disorders; liver conditions; mental health; other neurological conditions; public health; rare diseases; and respiratory conditions. 

THE QUESTIONNAIRE

Industry-wide questions:

  • How the pharma industry’s corporate reputation compares with that of other healthcare industries.
  • How the pharma industry’s corporate reputation has changed over the past five years.
  • How good or bad the pharma industry is at various activities of relevance to patients and patient groups.

7 indicators show the corporate reputation of individual pharma companies:

  • Patient centricity.
  • Information for patients.
  • Patient safety.
  • Usefulness of products.
  • Transparency.
  • Integrity.
  • Patient-group relationships (new for 2016).

INDUSTRY-WIDE FINDINGS

  • Just 28.4% of 2016's 99 respondent Spanish patient groups thought that the pharma industry had an “Excellent” or “Good” corporate reputation (37.9% of patient groups worldwide thought the same).
  • Only 21% of Spanish patient groups thought in 2016 that the pharma industry’s corporate reputation had improved over the past five years (compared with 23% of respondents worldwide). As many as 34% of Spanish patient groups thought in 2016 that pharma’s corporate reputation had declined (against 29% worldwide).
  • Spanish patient groups were more negative than patient groups worldwide in 2016 about many of the pharma industry’s activities. Although 53% stated that pharma was “Excellent” or “Good” at creating high-quality products, the figure is lower than those reported by patient groups from most of the 19 other countries/regions considered by this 2016 Corporate Reputation analysis.
  • Spanish patient groups sent pharma a clear message in 2016: the key task for improving corporate reputation (out of a list of 15 potential choices) is to improve its patient-group relations (25%). The equivalent figure in 2016 among patient groups worldwide was 19%.

PHARMA COMPANIES and SPANISH PATIENT GROUPS

The company with which Spanish patient groups were most familiar in 2016 was Pfizer (54 of the 99 respondent Spanish patient groups were familiar with the company). Janssen was the company which worked with the largest number of Spanish patient groups—25, in total.
Levels of familiarity, and partnership, with the 11 pharma companies among Spanish patient groups, 2016, Number of patient groups

INDIVIDUAL COMPANY FINDINGS—SPAIN

  • Janssen ranked overall 1st in 2016 for corporate reputation among the 11 pharma companies, when judged by Spanish patient groups familiar with the company (the year before, Janssen had also ranked 1st among the 14 pharma companies included in the 2015 Spain analysis). In addition, Janssen ranked 1st in 2016 for five of the seven indicators of corporate reputation: patient centricity; patient information; patient safety; the provision of high-quality products; and patient-group relationships.
  • AbbVie ranked 1st in 2016 for the other two indicators of corporate reputation: transparency and integrity (when judged by Spanish patient groups familiar with the company).

HIGHS and LOWS—SPAIN

Pharma companies’ PCRIs among Spanish patient groups familiar with each company, 2016 v. 2015: ordered according to the difference between the PCRI values for the two years (high to low)

  • When PatientView’s Patient Corporate Reputation Index (PCRI) is applied, the final 2016 rankings of companies among Spanish patient groups familiar with them can be compared with those attained by the same companies among Spanish patient groups responding to the 2015 survey.
  • Janssen in 2016 maintained its 2015 PCRI ranking of 1st among Spanish patient groups.
  • AbbVie also retained in 2016 its 2015 PCRI ranking of 2nd among Spanish patient groups.
  • The PCRI shows that Novartis, GSK, and Pfizer were the fastest risers up the overall corporate-reputation ranks (from the perspective of Spanish patient groups), 2015-2016.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Eli Lilly
  • GSK
  • Janssen
  • Merck & Co
  • MORE

Executive summary.
Spanish patient-group relationships with 11 pharma companies.
Industry-wide findings from Spanish patient groups.
Spanish patient groups on improving corporate reputation.
Rankings of the 11 pharma companies among Spanish patient groups FAMILIAR with them.
Positioning of the 11 pharma companies among PARTNER Spanish patient groups.
Profiles of the 11 pharma companies.
Comments from respondent Spanish patient groups.
Profile of the 99 respondent Spanish patient groups.

COMPANY PROFILES

Charts and tables for each of the 11 pharma companies:

  • The company’s best indicators of corporate reputation among Spanish patient groups, 2016.
  • Number of Spanish patient groups claiming familiarity with the company, 2016.
  • Number of Spanish patient groups saying that they had a working relationship with the company, 2016.
  • Profile of the respondent Spanish patient groups familiar with the company: therapy areas, and geographic remit.
  • Percentage of the Spanish patient groups that worked with the company—but which also worked with other companies, 2016.
  • The company’s average score for the indicators of corporate reputation among Spanish patient groups familiar with the company, 2016 v. 2015.
  • The company’s scores among Spanish patient groups familiar with the company, and which worked with the company, for each of the seven indicators of corporate reputation, 2016.
  • The company’s overall rankings for corporate reputation among patient groups familiar with the company: Spain v. worldwide. All 2016.
  • The company’s positioning for corporate reputation among patient groups which worked with the company: Spain v. worldwide. All 2016.
  • The company’s rankings among patient groups for the seven indicators of corporate reputation, 2016: Spain v. worldwide; familiar with v. worked with.
  • Performance of the company at corporate reputation in different therapy areas, compared with its own average among Spanish patient groups, 2016
  • The company’s Patient Corporate Reputation Index (PCRI) among Spanish patient groups, 2015 v. 2016.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  •  AbbVie
  •  Bayer
  •  Eli Lilly
  •  GSK
  •  Janssen
  •  Merck & Co
  •  Novartis
  •  Pfizer
  •  Roche
  •  Sandoz
  •  Sanofi
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll